Diagnosis of human malignances associated with activating mutations of platelet derived growth factor receptor alpha (PDGFRA)

Case ID:
0614
Web Published:
9/16/2020
Description:

Summary

The current technology consists of several novel PDGFRA variant proteins, and nucleic acids encoding these variants along with methods of using these molecules in detecting biological conditions associated with an activating PDGFRA mutation.

Technology Overview

Tyrosine kinases are expressed in many human cancers and are attractive targets for the development of anticancer therapies. Clinical response to these therapies is often correlated with the mutational status of the target.  The identification of a particular mutation in a patient’s tumor therefore can be used to identify which patients are most likely to respond to treatment. 

 OHSU investigators have discovered novel mutations of a type III receptor tyrosine kinase, platelet derived growth factor receptor alpha (PDGFR alpha, PDGFRα, PDGFRA) that result in activation of this tyrosine kinase. This technology provides methods and kits of identifying novel PDGFR alpha proteins and nucleic acids encoding these variants in human samples.

 PDGFR alpha mutations identified in gastrointestinal stromal tumors (GISTs) include: 

  •  D842V
  • DIMH842-845 (deletion)
  • HDSN845-848P (deletion)
  • V561D
  • ER561-562 (insertion)
  • RVIES560-564 (deletion)
  • SPDGHE566-571R (deletion)

Publications

Heinrich MC, et al. "PDGFRA activating mutations in gastrointestinal stromal tumors."  Science, 2003 299(5607):708-710. Link

 Licensing Opportunity

This technology is available for licensing.

 

Patent Information:
Category(s):
Diagnostics
For Information, Contact:
Anne Carlson
Assoc Dir, Tech Dev & Licensing
Oregon Health & Science University
503-494-7809
carlsann@ohsu.edu
Inventors:
Michael Heinrich
Christopher Corless
Jonathon Fletcher
George Demitri
Keywords:
Diagnostics
© 2023. All Rights Reserved. Powered by Inteum